ENDO ANNOUNCES COMMERCIAL AVAILABILITY OF OPANA ER (OXYMORPHONE HCL) EXTENDED-RELEASE AND OPANA (OXYMORPHONE HCL) IMMEDIATE-RELEASE TABLETS CII

Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc., has announced the commercial availability of Opana ER and Opana tablets. Endo has begun shipments to its customers and is instituting a wholesale and retail stocking program to ensure these products are distributed to retail pharmacies across the U.S. over the next several weeks.
Drug Newswire